Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is a biopharmaceutical company with a wide range of opportunities in various therapeutics areas, including diabetes, pulmonary hypertension, and chronic kidney disease. The recent positive Phase 1 data for inhaled nintedanib, the approval of the Furoscix autoinjector, and the launch of Afrezza in type 1 diabetes are all indicators of MNKD's potential for success in the market, particularly in the treatment of IPF which presents a compelling long-term opportunity. The company also has a strong license agreement in place for their commercialized product, Afrezza, and has promising options for future pipeline expansion, such as PPF and the potential for additional in-house programs. Additionally, MNKD's recently reported first quarter results may not have met expectations, but they do not change the overall positive outlook for the company's potential revenue streams, collaboration opportunities, and upcoming catalysts. Overall, there is a favorable risk-reward potential for investors, which is reflected in the increase in price target for MNKD.

Bears say

MannKind is facing several risks that may affect its future profitability and stock valuation, including potential issues with commercial execution, clinical trial results, and regulatory approvals. Additionally, the company's reliance on partnerships for the commercialization of its key treatments could limit its control and impact its overall valuation. Despite a discounted cash flow model projecting a $10 stock price, these risks may hinder the company's ability to achieve this target.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.